Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    CV9104
Show Display Options
Rank Status Study
1 Active, not recruiting Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: CV9104;   Biological: Placebo
2 Terminated An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
Condition: Prostate Carcinoma
Interventions: Biological: CV9104;   Device: needle free injection device (Tropis®)

Study has passed its completion date and status has not been verified in more than two years.